http://www.fpnotebook.com/
Inhaled InsulinAka: Insulin Inhalation Powder, Exubera
- Background
- Off U.S. Market as of October 2007 (based on business decisions, not on recall)
- Listed for historical reasons
- Indications
- Diabetes Mellitus when intollerant to SQ injection
- Mechanism
- Dry powder form of rapid acting Insulin
- Delivery by oral inhalation
- Large doses needed due to inefficient absorption
- Most Insulin remains in lung and is inactive
- Dosing
- Powder 1 mg (in Blister pack) = Insulin 3 units
- Powder 3 mg (in Blister pack) = Insulin 8 units
- Preparations
- Starter: Inhaler/parts, 180 packs 1 mg, 90 packs 3 mg
- Refill 12: 90 packs 1 mg, 90 packs 3 mg (990 units)
- Refill 15: 180 packs 1 mg, 90 packs 3 mg (1260 units)
- Cost: Expensive (twice the cost of SQ Insulin)
- Starter: $190
- Refills: $140-180
- Efficacy
- Similar to SC Insulin
- Adverse Effects
- Hypoglycemia (esp. when used with Oral Hypoglycemics)
- Cough (<5%)
- Chest Pain (<5%)
- Dyspnea (<5%)
- Dry Mouth (<5%)
- Monitoring: Pulmonary Function Tests
- Schedule: Baseline, 6 months and annually
- References
- Borja (2007) Am Fam Physician 75:1546
- Cefalu (2001) Ann Intern Med 134:203
- Quattrin (2004) Diabetes Care 27:2622
|
|---|
| Concepts | Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
, Hormone (T125)
|
| English | Exubera |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree